ORGANOX LIMITED

• ◆

  10 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing covers about 12 months versus 8 months prior. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Having made relevant and appropriate enquiries, including consideration of the Company's and Group's current cash resources and the working capital forecast, the Directors have a reasonable expectation that the Company and Group will have adequate cash resources to continue to meet the requirements of the business until at least 30 June 2026. Accordingly, the Board continues to adopt the going concern basis in preparing consolidated financial statements.”

Group structure

1. ORGANOX LIMITED · parent
   1. OrganOx Inc 1% · USA · support OrganOx Limited from the US with the research, development and commercialisation of OrganOx's proprietary technology of normothermic machine perfusion
   2. OrganOx (Europe) Limited 1% · United Kingdom · commercialise in the UK and Europe

Significant events

• “In July 2023 the Group secured additional equity funding through the successful raise of £25.0 million.”
• “OrganOx (Europe) Limited was incorporated on 17 September 2024 to support sales across Europe and Australia.”
• “In November 2024 the Company announced an exclusive clinical co-development agreement with eGenesis.”
• “In February 2025 the Company secured additional equity funding through the successful raise of $25.0 million gross, $20.0m net of expenses, to accelerate growth opportunities.”
• “On 24 February 2025, and immediately prior to a private placement process, the Company's share classes were converted into ordinary shares of £0.01 each. The H Ordinary shares, J Ordinary shares and L Ordinary shares converted to ordinary shares of £0.01 each on a 1-for-1 basis. The 26,598 G Ordinary shares converted to 26,173 ordinary shares of £0.01 each and 13,724 deferred shares of £0.01 each.”
• “At completion, the Company allotted 74,745 preferred shares of £0.01 each for a total consideration of $25.0 million. At the same time, 351,027 ordinary shares were transacted in a secondary market and the shares converted to 351,027 preferred shares in the hands of the buyers.”
• “On 31 March 2025, 351,027 ordinary shares were transacted in a secondary market and the shares converted to 351,027 preferred shares in the hands of the buyer.”
• “On 7 May 2025, 34,385 ordinary shares were transacted in a secondary market and the shares converted to 34,385 preferred shares in the hands of the buyer.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

0

last 24 months

Officers appointed

5

last 12 months

Officers resigned

10

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.